Core Viewpoint - The company has successfully developed and validated two innovative topical active ingredients for hair loss prevention and regrowth, leveraging its industry-leading AI molecular discovery platform, addressing a growing global market of over 2.5 billion people suffering from hair loss [1] Group 1: Product Development - The two active ingredients developed are small molecule Remeanagen™ (XTP-118) and peptide AquaKine™ (XTP-016) [1] - The combination of these "twin star" molecules has shown significant improvements in hair regrowth and prevention efficacy, safety, and onset speed compared to existing products [1] - Both molecules have successfully passed the INCI registration in the United States, and the combined product Groland has received FDA cosmetic registration [1] Group 2: Market Potential - The global hair loss population is over 2.5 billion and continues to grow, indicating a substantial market opportunity for effective products [1] - The company's AI platform is now entering the consumer health sector, which has significant potential for growth alongside its ongoing drug development for major diseases [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 XtalPi Holdings Limited （ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （股份代號：2228） 晶泰控股有限公司 自願性公告 晶泰AI創新研發平台成功開發生髮「雙子星」新分子， 獲得關鍵國際認證 本公告由晶泰控股有限公司（「本公司」或「晶泰」，連同其子公司統稱「本集團」） 自願作出。本公告旨在讓本公司股東及潛在投資者知悉本集團的最新業務發 展狀況。 根據聯合國人口預測及艾瑞咨詢，目前全球脫髮人群超過25億並逐年增加，但 市場缺乏有效產品。本公司董事會（「董事會」）欣然宣佈，本集團憑借其行業領 先的AI分子發現平台，成功開發並驗證了兩款兼具防脫和生髮的創新外用功效 成分 — 小分子Remeanagen™ (XTP-118)及多肽AquaKine™ (XTP-016）。這對「雙子 星」分子的聯用配方，經嚴謹人體實驗證明，在生髮防脫效果、安全性及起效 速度上均顯著超越現 ...